SCHEMBL2866076

SCHEMBL2866076

CCOC(=O)c1c(SC)nc2c(Cl)nccn12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
HPGD P15428 6/20 0.43
KDM4E B2RXH2 6/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPK1 P28482 3/20 0.41
MAPT P10636 3/20 0.41
HCRTR1 O43613 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
RAB9A P51151 1/20 0.41
CYP1A2 P05177 3/20 0.40
CYP2C9 P11712 3/20 0.40
CYP2C19 P33261 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16447922 0.85 SMN1; SMN2 (0.60) ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10
SCHEMBL2870571 0.84 ALDH1A1 (0.43) ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10
SCHEMBL2865146 0.82 CSNK1E (0.41) SMN1; SMN2MEN1KMT2ALMNAL3MBTL1
SCHEMBL2869370 0.81 SMN1; SMN2 (0.55) ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10
SCHEMBL14329205 0.77 KDM5B (0.43) ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10
SCHEMBL2866056 0.77 SMN1; SMN2 (0.56) ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10
SCHEMBL6937023 0.75 KDM5B (0.42) ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10
SCHEMBL31040052 0.75 KDM5B (0.42) ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10
SCHEMBL2866010 0.73 CSNK1E (0.39) ALDH1A1SMN1; SMN2RAB9AKMT2ALMNA
SCHEMBL2864657 0.73 PTK2 (0.34) ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772249-B2 Imidazo[1,2-b]pyridazine compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-10 US disclosed
US-20090181985-A1 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-07-16 US disclosed
US-20060211696-A1 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-09-21 US disclosed
US-7078405-B2 Imidazo[1,2-b]pyridazine compound EISAI CO., LTD. (JP) 2006-07-18 US disclosed
US-20040082781-A1 Bicyclic nitrogenous fused-ring compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-04-29 US disclosed
EP-1364952-A1 BICYCLIC NITROGENOUS FUSED-RING COMPOUND Eisai Co., Ltd. (JP) 2003-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211696-A1 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND CRHR1, CRHR2, CRH ALDH1A1 4011/4885HPGD 2368/4885KDM4E 3054/4885
US-20090181985-A1 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND CRHR1, CRHR2, CRH ALDH1A1 4011/4885HPGD 2368/4885KDM4E 3054/4885
US-20040082781-A1 Bicyclic nitrogenous fused-ring compound CRHR1, CRH, CRHR2 ALDH1A1 3803/4885HPGD 2874/4885KDM4E 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.